The Barostim device made by CVRx is headed for a U.S. pivotal trial this fall after acing an early feasibility study, researchers said today at the annual Heart Rhythm Management conference in Boston.
The principal investigator in an early feasibility study of CVRx's Barostim device said today that the company won FDA approval for a pivotal trial later this year, after reporting strong results from an early feasibility trial of the device.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1cDOOn7
Cap comentari:
Publica un comentari a l'entrada